These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21266799)

  • 21. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV; Exter BP; Steinberg M; Jarvis CI
    Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D; Gregoriou S; Makris M; Ioannides D
    Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
    Zhou H; Hu C; Zhu Y; Lu M; Liao S; Yeilding N; Davis HM
    J Clin Pharmacol; 2010 Mar; 50(3):257-67. PubMed ID: 19934030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
    Kurzeja M; Rudnicka L; Olszewska M
    Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
    Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract]   [Full Text] [Related]  

  • 30. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel biologic therapies in development targeting IL-12/IL-23.
    van de Kerkhof PC
    J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():5-9. PubMed ID: 20831703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE; Girolomoni G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.
    Adelzadeh L; Jourabchi N; Wu JJ
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):846-52. PubMed ID: 25081573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of severe psoriasis with ustekinumab during pregnancy.
    Andrulonis R; Ferris LK
    J Drugs Dermatol; 2012 Oct; 11(10):1240. PubMed ID: 23134993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS; Horn EJ; Cather JC
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case presentation of moderate-severe psoriasis.
    Salmhofer W
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():19-20. PubMed ID: 22758914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
    de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
    Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis].
    Amy de la Bretèque M; Appere-De Vecchi C; Zeboulon C; Zaien I; Sigal ML; Mahé E
    Ann Dermatol Venereol; 2015 Mar; 142(3):193-6. PubMed ID: 25624139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical tacrolimus induced extensive varicella zoster infection.
    Bovenschen HJ; Groeneveld-Haenen CP
    Dermatol Online J; 2011 Dec; 17(12):5. PubMed ID: 22233741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
    Zaghi D; Krueger GG; Callis Duffin K
    J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.